CureGene Doses First Patient in US Pivotal Trial of Evategrel for Cardiovascular and Cerebrovascular Diseases

CureGene Pharmaceutical has announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), the company's investigational antiplatelet therapy.

The milestone marks an important step in the development of Evategrel and moves the program closer to a future New Drug Application (NDA) submission in the United States.

The company believes the therapy could offer a new treatment option for patients living with cardiovascular and cerebrovascular diseases, which remain among the leading causes of death and disability worldwide.

Evategrel Designed to Address Long-Standing Treatment Challenges

Evategrel is the lead drug candidate developed using CureGene's proprietary A-proX Prodrug Platform.

According to the company, it is the world's first P2Y12 receptor inhibitor available in both intravenous and oral formulations. This dual-formulation approach is intended to provide greater flexibility for different treatment settings and patient needs.

The drug uses a thiol-hydrolyzing prodrug design and is activated by hydrolase enzymes that are widely present throughout the human body. Unlike several currently available therapies, Evategrel does not rely on the CYP450 enzyme pathway for activation.

This mechanism is designed to overcome several challenges associated with existing antiplatelet therapies, including clopidogrel resistance, delayed onset of action, variability in patient response, and the risk of drug-drug interactions.

US Registrational Trial Now Underway

The ongoing U.S. registrational study will evaluate both the injectable and oral capsule formulations of Evategrel.

Researchers will compare the efficacy and safety of Evategrel against clopidogrel in patients with several cardiovascular and cerebrovascular conditions.

The study includes patients with acute coronary syndrome (ACS), recent myocardial infarction, ischemic stroke, and peripheral arterial disease.

Results from the trial are expected to provide key clinical evidence needed for future regulatory submissions in global markets.

Earlier Studies Highlighted Key Benefits

Previous clinical studies have generated encouraging results for Evategrel.

One of the reported advantages is its rapid onset of action, which may help provide faster platelet inhibition compared to conventional therapies.

The drug has also demonstrated strong potency at relatively low doses, supporting its potential effectiveness in preventing blood clot-related events.

In addition, CureGene reported that clinical studies have shown a favorable safety profile, including a low risk of bleeding and minimal interaction with other medications.

These characteristics could make the therapy particularly useful for elderly patients and individuals managing multiple chronic conditions who often require several medications at the same time.

Company Sees Potential to Transform Antiplatelet Therapy

Commenting on the milestone, CureGene Founder and Chief Executive Officer Dr. Gongxin He described the first patient dosing as a major achievement for the company's global drug development efforts.

He noted that existing treatment options still leave significant unmet medical needs in cardiovascular and cerebrovascular diseases.

According to Dr. He, Evategrel's novel mechanism of action and availability in both injectable and oral forms may allow it to play an important role in the future treatment landscape for patients requiring antiplatelet therapy.

Development Also Progressing in China

While the U.S. trial moves forward, CureGene is also advancing Evategrel's development program in China.

The company has already received clinical trial authorization from China's Center for Drug Evaluation (CDE).

A Phase II clinical trial evaluating Evategrel in patients with ischemic stroke is expected to begin soon.

CureGene stated that parallel development efforts in both the United States and China are intended to support future simultaneous regulatory submissions and accelerate global market access opportunities.

Focus on Cardiovascular and Stroke Patients

Cardiovascular and cerebrovascular diseases affect hundreds of millions of people globally and continue to place a significant burden on healthcare systems.

With the start of the pivotal U.S. study, CureGene is aiming to generate the clinical evidence needed to support a new generation of antiplatelet treatment options that could provide faster action, more predictable responses, and improved convenience for patients and healthcare providers.

The company believes Evategrel has the potential to become an important addition to the treatment options available for patients at risk of serious cardiovascular and cerebrovascular events.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!